Related Experiment Videos

Why does atorvastatin inhibit renal crystal retention?

Masao Tsujihata1, Iwao Yoshioka, Akira Tsujimura

  • 1Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan. Tsujihata@uro.med.osaka-u.ac.jp

Urological Research
|March 15, 2011
PubMed

Insights

Atorvastatin prevents kidney stone formation by reducing crystal retention. This cholesterol drug increases antioxidant enzymes and decreases inflammatory markers, offering a potential treatment for calcium oxalate urolithiasis.

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Background:

  • Oxalate-induced renal tubular cell injury and crystal retention are key factors in kidney stone formation.
  • Atorvastatin has shown potential in preventing these issues, but its precise mechanism requires elucidation.

Purpose of the Study:

  • To investigate the underlying mechanism by which atorvastatin inhibits renal crystal retention in a rat model.
  • To evaluate the effects of atorvastatin on oxidative stress markers and inflammatory pathways involved in calcium oxalate urolithiasis.

Main Methods:

  • Utilized the ethylene glycol-induced hyperoxaluria model in male Sprague-Dawley rats.
  • Administered atorvastatin and analyzed kidney tissues for superoxide dismutase (SOD) and catalase levels.
  • Assessed NADPH oxidase (NOX-1) mRNA expression via real-time PCR.
  • Quantified transforming growth factor-β (TGF-β) levels in kidney tissue.

Main Results:

  • Atorvastatin treatment significantly increased SOD and catalase levels compared to the control group.
  • Expression of NOX-1 mRNA was decreased following atorvastatin administration.
  • Atorvastatin treatment suppressed the levels of TGF-β in kidney tissue.
  • Atorvastatin effectively inhibited calcium oxalate (CaOX) urolithiasis formation.

Conclusions:

  • Atorvastatin inhibits calcium oxalate urolithiasis by enhancing antioxidant capacity (increasing SOD and catalase) and reducing pro-inflammatory signaling (inhibiting TGF-β and NADPH oxidase).
  • These findings suggest atorvastatin as a promising therapeutic agent for treating calcium oxalate urolithiasis.

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
134
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
4.7K